NCT05882695View on ClinicalTrials.gov

Study of SPG302 in Healthy Volunteers and ALS Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

July 3, 2023

Primary Completion Date

June 27, 2025

Study Completion Date

June 27, 2025

Conditions
Amyotrophic Lateral Sclerosis
Interventions
DRUG

SPG302

synthetic small molecule

DRUG

Placebo

Placebo

Trial Locations (4)

2109

Macquarie University, North Ryde

3004

Nucleus Melbourne (healthy volunteers), Melbourne

4029

Royal Brisbane and Women's Hospital, Herston

5042

Flinders Medical center, Adelaide

Sponsors

Lead Sponsor

Spinogenix
All Listed Sponsors
collaborator

Novotech (Australia) Pty Limited

INDUSTRY

lead

Spinogenix

INDUSTRY